8-K: Amwell Announces 1-for-20 Reverse Stock Split to Regain NYSE Compliance

Amwell's board has approved a 1-for-20 reverse stock split to regain compliance with the NYSE's minimum share price requirement, effective July 10, 2024.

Summary

• American Well Corporation (Amwell) has announced a 1-for-20 reverse stock split of its Class A, Class B, and Class C common stock.
• The reverse stock split was approved by the board on June 27, 2024, and is expected to take effect on July 10, 2024, at 5:00 p.m. Eastern Time.
• Trading on a split-adjusted basis will begin on July 11, 2024, under the existing ticker symbol AMWL.
• The primary reason for the reverse stock split is to regain compliance with the New York Stock Exchange's (NYSE) minimum average closing price requirement of $1.00.
• The reverse stock split will reduce the number of outstanding Class A shares from approximately 266,174,000 to 13,308,700, Class B shares from 27,390,397 to 1,369,519, and Class C shares from 5,555,555 to 277,777.
• The reverse stock split will not change the par value of the common stock, which remains at $0.01 per share.
• Fractional shares will not be issued; instead, shareholders will receive a cash payment for any fractional shares they would have been entitled to.

Sentiment

Score: 5

Explanation: The document is neutral, focusing on a necessary action to maintain listing compliance. While the company expresses hope for future benefits, the primary driver is a response to a low share price, which is not inherently positive.

Positives

• The reverse stock split is expected to help Amwell regain compliance with the NYSE's minimum share price requirement.
• The company hopes to broaden its investor base as a result of the reverse stock split.
• The reverse stock split is part of a broader strategy to achieve greater efficiencies, optimized cash flow, and profitable growth.

Negatives

• The reverse stock split is primarily driven by the need to comply with NYSE listing standards, which suggests the company's share price has been under pressure.
• The reverse stock split will reduce the number of outstanding shares, which could be perceived negatively by some investors.

Risks

• The company's ability to regain and maintain compliance with NYSE listing standards is not guaranteed.
• There are risks associated with transitioning clients to the Converge platform without significant attrition.
• The company faces risks related to renewing and upselling its client base.
• The continuation of the Defense Health Agency (DHA) relationship beyond July 2025 with comparable financial terms is not assured.
• The telehealth market is experiencing weak growth and increased volatility.
• The company must adapt to rapid technological changes and increased competition.
• Changes in healthcare laws, regulations, or trends could impact the company's operations.
• The company faces potential liability from cybersecurity breaches.
• The company's ability to comply with federal and state privacy regulations is critical.

Future Outlook

The company aims to broaden its investor base and achieve greater efficiencies, optimized cash flow, and profitable growth through the reverse stock split. However, the company acknowledges several risks and uncertainties that could impact future results.

Management Comments

• Robert Shepardson, Amwell CFO, stated that the split has no direct impact on the company's market capitalization.
• Management hopes to broaden the base of potential investors in Amwell as they strive for greater efficiencies, optimized cash flow and profitable growth.

Industry Context

The reverse stock split is a measure taken by Amwell to maintain its listing on the NYSE, which is a common issue for companies in the volatile telehealth sector. The company is also focused on transitioning to its Converge platform and maintaining key client relationships, which are critical for growth in the competitive digital health market.

Comparison to Industry Standards

• Reverse stock splits are not uncommon for companies facing delisting from major exchanges due to low share prices, particularly in the technology and healthcare sectors.
• Other companies in the telehealth space, such as Teladoc Health and Livongo (now part of Teladoc), have also faced challenges related to market volatility and growth expectations.
• Amwell's focus on platform transition and client retention is consistent with industry trends, where companies are striving to build comprehensive and sticky solutions.
• The company's emphasis on hybrid care delivery aligns with the broader industry shift towards integrated digital and in-person healthcare services.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but the overall value of their holdings should remain the same immediately after the split.
• The reverse stock split is intended to help the company maintain its listing on the NYSE, which is important for investor confidence.
• The company's ability to regain compliance with NYSE listing standards is important for the long-term viability of the company.

Next Steps

• The reverse stock split will become effective on July 10, 2024, at 5:00 p.m. Eastern Time.
• Trading on a split-adjusted basis will begin on July 11, 2024.
• The company will continue to focus on transitioning clients to the Converge platform and maintaining key client relationships.

Key Dates

Keywords

reverse stock split, NYSE compliance, stock split, AMWL, share price, telehealth, healthcare, digital health, common stock